1,721,421 research outputs found
Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases?
No full textFocus on Remitting distal extremity swelling with pitting edem
Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies
No full textTwo sets of criteria have been proposed and widely accepted in the last few years for the classification of the whole spectrum of spondyloarthropathy, including the undifferentiated forms. These classification criteria--the Amor criteria and the European Spondyloarthropathy Study Group criteria--are not, however, particularly helpful for diagnosis because they do not include the milder and monosymptomatic forms. Outcomes research in spondyloarthritis is growing, and new instruments have been suggested. An international study group of experts is working to propose a core set of measures to be included in future clinical trials on ankylosing spondylitis. Intrasynovial corticosteroid injections in the sacroiliac joints may represent a valid alternative for patients with inflammatory low back pain that is unresponsive to nonsteroidal anti-inflammatory drugs. Sulfasalazine is an effective therapy for the psoriatic arthritis and peripheral arthritis of ankylosing spondylitis. A recent study has suggested its efficacy in reactive arthritis as well. In reactive arthritis, the use of long-term antibiotic therapy has been proposed and is under study
Distal musculoskeletal manifestations in polymyalgia rheumatica
No full textIn polymyalgia rheumatica (PMR) the marked and distinctive symptoms of proximal aching and stiffness have tended to draw attention away from the distal musculoskeletal manifestations which also occur in this syndrome. Peripheral manifestations are present in about half of all cases of PMR and include joint synovitis, diffuse swelling of the distal extremities with or without pitting edema, tenosynovitis and carpal tunnel syndrome. Awareness of these findings will help to facilitate the proper diagnosis and institution of appropriate therapy for this disease
More on remitting seronegative symmetrical synovitis with pitting edema as paraneoplastic syndrome
No full textFocus on remitting seronegative symmetrical synovitis with pitting edema as paraneoplastic syndrom
Shoulder sonographic findings in polymyalgia rheumatica
No full textTo describe shoulder sonographic findings in polymyalgia rheumatic
Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica
No full textTo determine if C-reactive protein, a direct measure of acute phase response, could be a more sensitive marker of disease activity than ESR in patients with polymyalgia rheumatica
RS3PE syndrome: an overview
No full textMore than ten years ago McCarty et al. described the RS3PE syndrome based on their study of 23 patients. Numerous additional cases have since been reported. In addition to the isolated or "pure" type which probably forms part of the clinical spectrum of polymyalgia rheumatica, inflammatory swelling with pitting edema of the dorsum of the hands and/or feet can be observed in different inflammatory rheumatic diseases as well as in haematological and solid malignancies
Disease-modifying antirheumatic drug therapy for psoriatic arthritis
No full textAs erosive and deforming arthritis is present in 40% of patients with psoriatic arthritis (PsA), early and aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) may be as effective in controlling the progression of the disease as it is for rheumatoid arthritis (RA). Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations. No controlled study has evaluated the efficacy of these drugs on the progression of radiological damage. It has recently been demonstrated that leflunomide and anti-tumor necrosis factor (TNF) agents are effective in PsA and psoriasis. The symptomatic improvement has been important and sustained and side effects minimal. In particular, inhibitors of TNF appear to have excellent potential to treat PsA. These agents are able to slow joint damage in rheumatoid arthritis and they are effective on spinal symptoms in ankylosing spondylitis. Hopefully, these findings will prove true in PsA as well
Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema
No full textRemitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a syndrome that may be associated with many conditions, including malignancy. Three further cases of paraneoplastic RS3PE are described and the literature is reviewed. Paraneoplastic RS3PE is more frequently associated with solid tumors, in particular adenocarcinoma. The two clinical characteristics suggestive of paraneoplastic RS3PE are systemic sign/symptoms and the poor response to corticosteroid therapy
- …
